FDA Approves Novel Targeted Therapy for Rare Blood Cancer

Published Date: 29 May 2026

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Read Full News

Latest News

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Researchers are testing CAR T-cell therapy as a way to reset the immune system in lupus, Graves’ disease and other conditions where the body’s defenses go rogue.

Todays Updates

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Todays Updates

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Latest News

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Researchers are testing CAR T-cell therapy as a way to reset the immune system in lupus, Graves’ disease and other conditions where the body’s defenses go rogue.

News All Time

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

QOL Maintained With Giredestrant Combo in Advanced BC

Giredestrant plus everolimus does not increase treatment burden in advanced breast cancer, new safety and patient-reported outcome data from the evERA BC trial show.

De-escalation Misses the Mark in Inflammatory Breast Cancer

Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Recommended News For You

Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer

Men With Prostate Cancer Experience Less Hot Flashes When Using an Affordable Drug.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

New surgical method shows promising results for cervical cancer treatment

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Recommended Articles For You

Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment 

Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management 

The Link Between Being Overweight and Cancer 

Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Which Risk Model Better Identifies High-Risk Smoldering MM?

2.

Study offers clearer picture of childhood brain tumor survival

3.

US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry

4.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

5.

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.

1.

Exploring the Latest Treatments for Desmoid Tumors

2.

Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment

3.

The Millionaire's Battle: Does Mark Cuban Have Cancer?

4.

Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer

5.

Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot